Get the Stockscreener App
44.10
3.55%
1.51
Kymera Therapeutics Inc stock is traded at $44.10, with a volume of 508.17K.
It is up +3.55% in the last 24 hours and down -3.63% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$42.59
Open:
$42.8
24h Volume:
508.17K
Relative Volume:
0.59
Market Cap:
$3.15B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-14.23
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+3.45%
1M Performance:
-3.63%
6M Performance:
+19.80%
1Y Performance:
-3.82%
1-Day Range:
$42.05
$44.50
1-Week Range:
$41.49
$44.50
52-Week Range:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
44.10 | 3.12B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics Inc. Stock Poised for Technical ComebackQuarterly Trade Report & Accurate Trade Setup Notifications - thegnnews.com
Kymera Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Is Kymera Therapeutics Inc. the Top Chart Pick This WeekWeekly Earnings Recap & Precise Trade Entry Recommendations - kangso.co.kr
Real time social sentiment graph for Kymera Therapeutics Inc.New Guidance & Free Accurate Trade Setup Notifications - Newser
What institutional flow reveals about Kymera Therapeutics Inc.Dividend Hike & Intraday High Probability Alerts - Newser
What indicators show strength in Kymera Therapeutics Inc.2025 Market Sentiment & Smart Investment Allocation Tips - Newser
Sentiment analysis tools applied to Kymera Therapeutics Inc.Weekly Stock Analysis & Weekly Top Gainers Trade List - Newser
What data driven models say about Kymera Therapeutics Inc.’s futureQuarterly Market Summary & Stepwise Entry/Exit Trade Alerts - Newser
Real time breakdown of Kymera Therapeutics Inc. stock performanceGlobal Markets & AI Forecast for Swing Trade Picks - Newser
Smart tools for monitoring Kymera Therapeutics Inc.’s price actionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely - 富途牛牛
News impact scoring models applied to Kymera Therapeutics Inc.Trade Entry Report & AI Enhanced Trading Alerts - Newser
Can technical indicators confirm Kymera Therapeutics Inc.’s reversalJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. reboundJuly 2025 Action & Weekly Return Optimization Alerts - Newser
Is Kymera Therapeutics Inc. building a consolidation base2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - Newser
Key resistance and support levels for Kymera Therapeutics Inc.Long Setup & Technical Pattern Alert System - Newser
How liquid is Kymera Therapeutics Inc. stock2025 Geopolitical Influence & AI Enhanced Trade Execution Alerts - kangso.co.kr
Kymera Therapeutics (NASDAQ:KYMR) Downgraded by Wall Street Zen to Sell - Defense World
Analysts Are Updating Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Estimates After Its Second-Quarter Results - Yahoo Finance
Signal strength of Kymera Therapeutics Inc. stock in tech scanners2025 EndofYear Setup & AI Driven Stock Movement Reports - Newser
Is Kymera Therapeutics Inc. stock ready for a breakoutJuly 2025 Breakouts & Long Hold Capital Preservation Plans - Newser
Kymera Therapeutics Inc. Stock Performance After Earnings: Historical InsightsWeekly Stock Summary & Smart Money Movement Alerts - Newser
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating - TipRanks
Best data tools to analyze Kymera Therapeutics Inc. stockJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
What makes Kymera Therapeutics Inc. stock price move sharplyInsider Selling & Weekly Top Gainers Trade List - Newser
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - Defense World
KYMR Q3 EPS Forecast Lifted by Brookline Capital Management - Defense World
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $54 to $57 - 富途牛牛
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Q3 Earnings Forecast for KYMR Issued By Leerink Partnrs - Defense World
Kymera Therapeutics Inc. Moves Into Overbought Range Analysts CautiousJuly 2025 Intraday Action & Risk Adjusted Swing Trade Ideas - sundaytimes.kr
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $59.11 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript - Insider Monkey
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - NewsBreak: Local News & Alerts
Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating - TipRanks
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Positive Outlook for Kymera Therapeutics Amid Promising KT-621 Developments and Strong Financial Position - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings - Defense World
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
What analysts say about Kymera Therapeutics Inc. stock outlookHigh Probability Trade Plan with Indicators - Newser
Multi factor analysis applied to Kymera Therapeutics Inc.Earnings Report Summary with Market Impact - Newser
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Extends Cash Runway, Boosts Funding through Immunology Pipeline Advancements and Collaborations. - AInvest
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kymera Therapeutics Inc Stock (KYMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Jun 30 '25 |
Buy |
44.00 |
655,500 |
28,842,000 |
6,117,295 |
| Ridloff Elena | Director |
Jun 11 '25 |
Option Exercise |
20.29 |
4,500 |
91,305 |
4,500 |
| Ridloff Elena | Director |
Jun 11 '25 |
Sale |
50.00 |
4,500 |
225,000 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):